Please join us for a Special Chemical Engineering Seminar
Distinguished Lecture Series

Friday, November 1, 2013
108 Snell Engineering
11:45 a.m. – 12:50 p.m.

“How Academia and the Pharmaceutical Industry Can Work Together”

MICHAEL ROSENBLATT, M.D.
Executive Vice President and Chief Medical Officer
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, NJ 08889

ABSTRACT

There is a long history of productive collaboration between biomedical scientists in academia and in the pharmaceutical industry. The primary beneficiary of this collaboration has been the public. Since the middle of the last century, marked advances in the treatment and prevention of disease have been driven by the translational research interactions across these two domains. But now, at a time when collaboration between academia and industry should be accelerating based on past success, new technology, and ever-increasing need, numerous obstacles to effective collaboration have appeared. In this analysis, based on experience in both academia and industry, the author provides perspective on current obstacles to academic–industrial collaboration, followed by recommendations on how effective collaboration can be renewed and enhanced.

BIOGRAPHY: Dr. Rosenblatt is Executive Vice President and Chief Medical Officer of Merck & Co., Inc. He is the first person to serve in this role for Merck. Previously, he served as Dean of Tufts University School of Medicine. Prior to that, he held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and BIDMC and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC. Prior to that, he served as Director of the Harvard-MIT Division of Health Sciences and Technology, and earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck’s bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy.

He is the recipient of the Fuller Albright Award and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. He was a member of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, to Fellowship in the American Association for the Advancement of Science and the American College of Physicians, and the presidency of the American Society of Bone and Mineral Research. From 1981 to 1984, he served as Chief of the Endocrine Unit, Massachusetts General Hospital. He received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were at the Massachusetts General Hospital.

Refreshments will be served.